Definitive Contract 75N93020C00044
Award Date 8/21/20
Potential Completion Date 10/22/21
Potential Value $297K
Federal Agency
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Woburn, MA 01801, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
9
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This SBIR Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, valued at $299,868, was awarded to Hbvtech of Germantown, Maryland. The contract supports research outlined in Topic 084 of the solicitation, which sought proposals for antiviral drugs to cure chronic hepatitis B virus infection. The firm-fixed price contract is a total small business set-aside running from August 2020 through October 2021. The award advances the NIH/NIAID's...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.55 million definitive cost plus fixed fee contract to Hbvtech of Germantown, Maryland to perform work under Small Business Innovation Research Phase II Topic 84, entitled "Antiviral Drugs to Cure Chronic Hepatitis B Virus Infection." The contract period of performance spans from September 1, 2022 through August 25, 2025. Under this award,...
- This is a $2,656,170 firm-fixed price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Hbvtech, L.L.C., a minority-owned small disadvantaged business located in Germantown, Maryland. The contract is for evaluating HBVZ10-based therapies for covalently closed circular DNA (cccDNA) clearance, focusing on the virological foundation and synergistic combinations. This contract was awarded under the SBIR (Small...
- This definitive contract from the Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) awards Regulus Therapeutics Inc. $300,000 under the SBIR PHS 2020-1 Topic 084 solicitation. The solicitation sought proposals to conduct research and development in support of developing antiviral drugs to cure chronic hepatitis B virus infection. This is a firm fixed price, total small business set-aside contract to be...
- <p>This is a $299,961.00 SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Cubit Diagnostics, Inc. (doing business as Arete Biosciences) for the development of an ultrasensitive, rapid, and easy-to-use at-home molecular test for Hepatitis C, Hepatitis B, and HIV. The contract has a firm fixed price and a completion date of April 30, 2025. It is designated as a Total Small Business set-aside contract.</p>
- This $299,889 firm fixed price definitive contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Esper Biosciences Inc. for hepatitis C diagnostics using nanopore field-effect sensors. The contract is being performed in Ithaca, NY from September 2021 through September 2023. It falls under a Small Business Innovation Research solicitation issued by the NIH and Centers for Disease Control and Prevention seeking proposals for...
- This is a $300,000 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Vitruvian Bio, LLC, a small disadvantaged woman-owned business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to be completed by June 30, 2023. The award is associated with a larger SBIR solicitation that sought innovative research proposals from small businesses to...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), to Pathovacs Inc., a small biotechnology company based in Ames, Iowa. The $393,833 firm-fixed-price contract supports the development of a prototype in vitro diagnostic device for qualitative screening of individuals for anti-hepatitis C virus (HCV) antibodies to determine HCV exposure. This aligns with the NCI's mission to...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Definitive Contract to CFD Research Corporation, a for-profit organization, to perform Phase I SBIR research on a "SMART BIOREACTOR FOR LARGE-SCALE HIGH TITER PHAGE PREPS" project. The contract has a potential value of $299,946.26 and a completion date of August 15, 2022. This SBIR award was not set aside for a specific business...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000 definitive contract to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, as part of the Small Business Innovation Research Program Phase I Action. The contract is a firm fixed price award with a period of performance from July 5, 2022 through November 30, 2023 to be performed in Canton, Massachusetts. The award is set aside for...